Bradley Foster & Sargent’s RxSight RXST Stock Holding History

Bradley Foster & Sargent’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-86,055	Closed	-$1.12M	–	556
2025 Q2	$1.12M	Buy	+86,055	New	+$1.29M	0.02%	279
2024 Q3	–	Sell	-25,270	Closed	-$1.52M	–	464
2024 Q2	$1.52M	Sell	25,270 -542	-2%	-$31K	0.03%	227
2024 Q1	$1.33M	Sell	25,812 -13,045	-34%	-$640K	0.02%	247
2023 Q4	$1.57M	Sell	38,857 -18,477	-32%	-$542K	0.03%	229
2023 Q3	$1.65M	Hold	57,334	–	–	0.03%	222
2023 Q2	$1.65M	Hold	57,334	–	–	0.03%	222
2023 Q1	$956K	Sell	57,334 -175	-0.3%	-$2.47K	0.02%	251
2022 Q4	$729K	Buy	57,509 +175	+0.3%	+$2.13K	0.02%	279
2022 Q3	$688K	Buy	57,334 +1,265	+2%	+$17.4K	0.02%	275
2022 Q2	$789K	Buy	56,069 +28,777	+105%	+$380K	0.02%	262
2022 Q1	$338K	Sell	27,292 -3,981	-13%	-$47.8K	0.01%	396
2021 Q4	$352K	Buy	31,273 +595	+2%	+$7.15K	0.01%	371
2021 Q3	$389K	Buy	+30,678	New	+$422K	0.01%	331

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bradley Foster & Sargent's RXST Position: Q3 2025 in Review

Bradley Foster & Sargent sold out of RxSight (RXST) in Q3 2025, closing a stake of 86,055 shares — an estimated $1.12M sold.

Bradley Foster & Sargent first reported a position in RXST in Q3 2021 and held it in 13 quarters. The position peaked at $1.65M in Q3 2023. 160 funds tracked by Wall St. Rank hold RXST as of Q3 2025.

Bradley Foster & Sargent reported no remaining RxSight position as of Q3 2025 after selling out during the quarter.
Bradley Foster & Sargent sold 86,055 RxSight shares in Q3 2025, an estimated $1.12M.
Bradley Foster & Sargent first reported a position in RxSight in Q3 2021 and held it in 13 quarters.
Bradley Foster & Sargent's RxSight position peaked at $1.65M in Q3 2023.
160 funds tracked by Wall St. Rank held RxSight as of Q3 2025.

Based on Bradley Foster & Sargent's 13F filing for Q3 2025, filed 10 Nov 2025.